U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis 08/25/2020 RECORDATI: RESULTS FROM THE PHASE III LINC-3 STUDY OF ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF CUSHING’S DISEASE PUBLISHED IN LANCET DIABETES & ENDOCRINOLOGY 07/28/2020 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE 06/17/2020 Pagination First page « First Previous page ‹ Previous … Page 8 Current page 9 Page 10 Page 11 … Next page Next › Last page Last »
U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis 08/25/2020
RECORDATI: RESULTS FROM THE PHASE III LINC-3 STUDY OF ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF CUSHING’S DISEASE PUBLISHED IN LANCET DIABETES & ENDOCRINOLOGY 07/28/2020
RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE 06/17/2020
